15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Tarsus Pharmaceuticals Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $88.00 to $100.00, so the covering firms are broadly aligned. The average target of $95.00 sits 9% above the current $87.28. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.04 next quarter toward $2.33 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Tarsus Pharmaceuticals Inc.
As of Sep, 5 of 5 firms rate TARS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TARS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.32 – $0.16 · 5 analysts · -78% YoY
Next period, 5 analysts expect Tarsus Pharmaceuticals Inc to earn $-0.04 a share (range $-0.32 – $0.16), versus $-0.20 a year earlier. Full-year consensus is $-2.13, growing to $2.33 the year after.
REVENUE · NEXT QUARTER
$196.9M
Range $191.6M – $202.3M · 5 analysts · +30% YoY
Revenue is expected to reach $196.9M (range $191.6M – $202.3M), +29.8% year-over-year. Full-year consensus is $713.6M, rising to $925.3M next year.
Top analysts covering Tarsus Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TARS.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #92
Buy
$88.00+0.8% to target
Overall win rate
54%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #125
Buy
$89.00+2.0% to target
Overall win rate
46%
+ Follow
#3
Oren Livnat
HC Wainwright & Co. · Rank #170
Buy
$73.00-16.4% to target
Overall win rate
54%
+ Follow
#4
Balaji Prasad
Barclays · Rank #178
Buy
$60.00-31.3% to target
Overall win rate
44%
+ Follow
#5
Francois Brisebois
Oppenheimer · Rank #215
Buy
$100.00+14.6% to target
Overall win rate
41%
+ Follow
TARS stock forecast FAQ
What is TARS's average 12-month price target?+
The 5 analysts with a live target average $95.00 for Tarsus Pharmaceuticals Inc over the next 12 months, ranging from a $100.00 high to a $88.00 low.
Is TARS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TARS?+
The Street-high target is $100.00 (Oppenheimer), and the Street-low is $88.00 (HC Wainwright & Co.). The average of all 5 active targets is $95.00.
How many Wall Street analysts cover TARS?+
5 analysts have an active rating on Tarsus Pharmaceuticals Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering TARS?+
Among analysts who currently cover TARS, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #92). Their current call is Buy with a $88.00 target.
What is Tarsus Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.32 – $0.16) across 5 analysts. Full-year EPS is projected at $-2.13, rising to $2.33 the following year.
How much revenue is Tarsus Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $196.9M (range $191.6M – $202.3M). Full-year revenue is projected at $713.6M, growing to $925.3M next year.
Have analysts been upgrading or downgrading TARS lately?+
As of Sep, 5 of 5 firms rate TARS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TARS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
